- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.
Jazz Pharmaceuticals (JAZZ) reported lower earnings and revenue for the 2016 second quarter and gave an outlook below Wall Street's expectations.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.